The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Controlled Clinical Trials

• Publication date

  2002-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0197-2456(01)00179-9PMID 11943448
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.

  2001cited by this paper
• A Randomized Trial of the Discontinuation of Primary and Secondary Prophylaxis against Pneumocystis carinii Pneumonia after Highly Active Antiretroviral Therapy in Patients with HIV Infection

  2001cited by this paper
• Closeout of four phase II Vanguard trials and patient rollover into a large international phase III HIV clinical endpoint trial.

  2001cited by this paper
• A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.

  2001cited by this paper
• A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.

  2000cited by this paper
• Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease.

  2000cited by this paper
• Discontinuation of prophylaxis against Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS.

  2000cited by this paper
• Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators.

  2000cited by this paper
• Antiretroviral Therapy in Adults Updated Recommendations of the International AIDS Society–USA Panel

  2000cited by this paper
• A randomized, controlled 24-week study of intermittent subcutaneous interleukin-2 in HIV-1 infected patients in Thailand

  2000cited by this paper
• Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with </=250/microL CD4 T cells and undetectable plasma virus load.

  1999cited by this paper
• A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.

  1999cited by this paper
• Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study.

  1999cited by this paper
• Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group.

  1999cited by this paper
• Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virologic Failure and Adverse Drug Reactions

  1999cited by this paper
• A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection.

  1999cited by this paper
• Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study. Australian IL-2 Study Group.

  1998cited by this paper
• Clinical and immunological features of human immunodeficiency virus infection in patients from Bangkok, Thailand.

  1998cited by this paper
• Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease

  1998cited by this paper
• Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.

  1998cited by this paper
• Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group.

  1998cited by this paper
• Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000

  1998cited by this paper
• Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

  1998cited by this paper
• HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies

  1997cited by this paper
• A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

  1997cited by this paper
• Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons.

  1997cited by this paper
• AIDS at a university hospital in Bangkok, Thailand.

  1996cited by this paper
• Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.

  1996cited by this paper
• Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus.

  1996cited by this paper
• Antiretroviral therapy in adults.

  1996cited by this paper
• Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection.

  1996cited by this paper
• Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma

  1996cited by this paper
• Serologic evaluation of human immunodeficiency virus type 1-infected individuals from Argentina and the United States indicates a similar distribution of subgroup B isolates

  1995cited by this paper
• The data and safety monitoring board and acquired immune deficiency syndrome (AIDS) clinical trials.

  1995cited by this paper
• Sample size calculation for complex clinical trials with survival endpoints.

  1995cited by this paper
• A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group.

  1995cited by this paper
• Considerations in choice of a clinical endpoint for AIDS clinical trials. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA).

  1994cited by this paper
• Opportunistic infections and AIDS-related conditions among people with AIDS / ARC in Thailand.

  1994cited by this paper
• Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group.

  1993cited by this paper
• Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter

  1993cited by this paper
• 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.

  1993cited by this paper
• Discrete sequential boundaries for clinical trials

  1983cited by this paper
• Random-effects models for longitudinal data.

  1982cited by this paper
• The Statistical Analysis of Failure Time Data

  1980cited by this paper
• A multiple testing procedure for clinical trials.

  1979cited by this paper
• Regression Models and Life-Tables

  1972cited by this paper
• FAST TRACK: A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome

  year unknowncited by this paper

• Derivation of a Protein Risk Score for Cardiovascular Disease Among a Multiracial and Multiethnic HIV+ Cohort

  2023cites this paper
• Interleukin 2 therapy in patients with HIV infection

  2019cites this paper
• Interleukin‐2 as an adjunct to antiretroviral therapy for HIV‐positive adults

  2017cites this paper
• Increasing procaspase 8 expression using repurposed drugs to induce HIV infected cell death in ex vivo patient cells

  2017cites this paper
• A characterisation of low-grade inflammation and metabolic complications in HIV-infected patients.

  2016cites this paper
• Discordant responses to cART in HIV-1 patients in the era of high potency antiretroviral drugs: clinical evaluation, classification, management prospects

  2016cites this paper
• Interaction of a Cannabinoid-2 Agonist With Tramadol on Nociceptive Thresholds and Immune Responses in a Rat Model of Incisional Pain

  2016cites this paper
• Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study

  2015cites this paper
• Interleukin-2 (IL-2) is a naturally-occurring immune system signaling molecule that promotes lymphocyte generation. Intravenous recombinant IL-2, called aldesleukin, has FDA approval for use in patients with metastatic renal cell carcinoma and metastatic melanoma. Aldesleukin also is being investiga

  2014cites this paper
• Severity of Cardiovascular Disease Outcomes Among Patients With HIV Is Related to Markers of Inflammation and Coagulation

  2014cites this paper
• Primary Efficacy Endpoint

  2014cites this paper
• Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population

  2013cites this paper
• Role of Interleukin-2 in Patients with HIV Infection

  2012cites this paper
• Reclassification of risk of death with the knowledge of D-dimer in a cohort of treated HIV-infected individuals

  2012cites this paper
• HIV RNA Suppression and Immune Restoration: Can We Do Better?

  2012cites this paper
• E-survey with researchers, members of ethics committees and sponsors of clinical research in Brazil: an emerging methodology for scientific research.

  2012cites this paper
• Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin‐2 in a Randomized International Trial (ESPRIT)

  2011cites this paper
• Empirical evaluation of the need for ‘on-going consent’ in clinical research

  2011cites this paper
• infection cycle entry and expansion in HIV-1 - IL-7 administration drives T cell

  2011cites this paper
• Fornecimento de medicamentos pós-pesquisa

  2011cites this paper
• Interleukin-2 therapy in patients with HIV infection.

  2010cites this paper
• Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV

  2010cites this paper
• Quality control of phenotypic forms data in the Type 1 Diabetes Genetics Consortium

  2010cites this paper
• The rise and fall of intermittent interleukin-2 therapy in HIV infection.

  2010cites this paper
• Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients

  2010cites this paper
• Designing and implementing sample and data collection for an international genetics study: the Type 1 Diabetes Genetics Consortium (T1DGC)

  2010cites this paper
• Changes in the levels of some acute‐phase proteins in human immunodeficiency virus‐1 infected patients, following interleukin‐2 treatment

  2010cites this paper
• Immunotherapies in HIV-1 infection

  2009cites this paper
• Interleukin-2 Therapy in Patients with HIV Infection

  2009cites this paper
• IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection.

  2009cites this paper
• Benefits and Burdens of Participation in a Longitudinal Clinical Trial

  2009cites this paper
• Interleukin-2 therapy in patients with HIV infection.

  2009cites this paper
• Interleukin-2 cycling causes transient increases in high-sensitivity C-reactive protein and D-dimer that are not associated with plasma HIV-RNA levels

  2009cites this paper
• Inferiority of IL-2 alone versus IL-2 with HAART in maintaining CD4 T cell counts during HAART interruption: a randomized controlled trial

  2009cites this paper
• Interleukin-2 before antiretroviral therapy in patients with HIV infection: a randomized trial (ANRS 119).

  2009cites this paper
• Select updates from the 16th CROI: treatment-related cardiovascular risk, pharmacokinetic issues, and interleukin-2 use.

  2009cites this paper
• Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials

  2009cites this paper
• Long-term clinical and surrogate marker effects of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients.

  2008cites this paper
• Determination of the Underlying Cause of Death in Three Multicenter International HIV Clinical Trials

  2008cites this paper
• Why Patients Continue to Participate in Clinical Research

  2008cites this paper
• The challenge of IL-2 immunotherapy in HIV disease: "no through road" or turning point?

  2008cites this paper
• TILT: a randomized controlled trial of interruption of antiretroviral therapy with or without interleukin-2 in HIV-1 infected individuals

  2008cites this paper
• HIV Latency and Reactivation: The Early Years

  2008cites this paper
• Indicator disease‐guided testing for HIV – the next step for Europe?

  2008cites this paper
• Why patients continue to participate in clinical research.

  2008cites this paper
• Loss to follow‐up in an international, multicentre observational study

  2008cites this paper
• The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.

  2007cites this paper
• Chapter 25 – Design of Outcome Studies

  2007cites this paper
• Predictors of CD4 count change over 8 months of follow up in HIV‐1‐infected patients with a CD4 count≥300 cells/μL who were assigned to 7.5 MIU interleukin‐2

  2007cites this paper
• Clinical outcomes in clinical trials of anti-HIV treatment

  2007cites this paper
• CD4+ T cell responses to interleukin-2 administration in HIV-infected patients are directly related to the baseline level of immune activation.

  2007cites this paper
• Long-term effects of intermittent interleukin-2 therapy in chronic HIV-infected patients (ANRS 048–079 Trials)*

  2007cites this paper
• Reduced Secondary Cytokine Induction by BAY 50-4798, a High-Affinity Receptor-Specific Interleukin-2 Analog

  2006cites this paper
• Post-trial Access to Tested Interventions: The Views of IRB/REC Chair, Investigators, and Research Participants in a Multinational HIV/AIDS Study

  2006cites this paper
• The CD4 lymphocyte count and risk of clinical progression

  2006cites this paper
• Immunological recovery and antiretroviral therapy in HIV-1 infection.

  2006cites this paper
• Interruption of antiretroviral therapy blunts but does not abrogate CD4 T-cell responses to interleukin-2 administration in HIV infected patients

  2006cites this paper
• The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) era

  2006cites this paper
• Evaluation of Subcutaneous Proleukin (Interleukin-2) in a Randomized International Trial (ESPRIT): Geographical and Gender Differences in the Baseline Characteristics of Participants

  2006cites this paper
• A Randomised Trial of Subcutaneous Intermittent Interleukin-2 without Antiretroviral Therapy in HIV-Infected Patients: The UK–Vanguard Study

  2006influential citation
• Interleukin-2: a potential treatment option for postherpetic neuralgia?

  2006cites this paper
• Reporting and Evaluation of HIV-Related Clinical Endpoints in Two Multicenter International Clinical Trials

  2006cites this paper
• Pulmonary pneumocystosis in a patient with greater than 500 CD4 cells/microl: a role for IL-2 therapy?

  2006cites this paper
• Interleukin-2 for the treatment of human immunodeficiency virus infection.

  2006cites this paper
• HIV-NAT Promoting Rational and Evidence-based Use of Antiretroviral Therapies

  2006cites this paper
• Promoting Rational and Evidence-based Use of Antiretroviral Therapies HIV-NAT

  2006cites this paper
• Effect of IL‐2 on hepatitis C virus RNA levels in patients co‐infected with human immunodeficiency virus receiving HAART

  2005cites this paper
• No effect of interleukin-2 on IgE levels given in addition to antiretroviral therapy in HIV-infected adults with CD4 >300 cells/mm3.

  2005cites this paper
• HIV-1 infected women in Europe.

  2005cites this paper
• HIV Medicine 2005

  2005cites this paper
• 3 – Quantitative Science

  2005cites this paper
• HIV disease progression in a patient cohort treated via a clinical research network in a resource limited setting

  2005cites this paper
• Pilot study of low-dose interleukin-2, pegylated interferon-alpha 2b, and ribavirin for the treatment of hepatitis C virus infection in patients with HIV infection.

  2005cites this paper
• In vivo expansion of CD4CD45RO-CD25 T cells expressing foxP3 in IL-2-treated HIV-infected patients.

  2005cites this paper
• Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients.

  2005cites this paper
• In vivo expansion of CD4+CD45RO–CD25+ T cells expressing foxP3 in IL-2-treated HIV-infected patients

  2005cites this paper
• Aktuelle Aspekte der HIV-Therapie

  2005cites this paper
• A DIAGNOSTIC STUDY OF NOCARDIOSIS PATIENTS BEING CONFINED IN SHAREATI TRAINING HOSPITAL IN TEHRAN, USING CULTURAL & SEROLOGICAL METHODS

  2005cites this paper
• Effects of highly active antiretroviral therapy among HIV-infected patients

  2004cites this paper
• The use of growth factors and cytokines to treat opportunistic infections in HIV-1 disease.

  2004cites this paper
• Induction and maintenance therapy with intermittent interleukin-2 in HIV-1 infection.

  2004cites this paper
• Graves' Disease after Interleukin-2 Therapy in a Patient with Human Immunodeficiency Virus Infection

  2004cites this paper
• Effects of highly active antiretroviral therapy among HIV-infected patients. Results from randomised and observational studies.

  2004cites this paper
• CD4 cell response to 3 doses of subcutaneous interleukin 2: meta-analysis of 3 Vanguard studies.

  2004cites this paper
• Clinical trial methodology and clinical cohorts: the importance of complete follow-up in trials evaluating the virological efficacy of anti-HIV medicines

  2004cites this paper
• Biostatistics: A Series of References and Textbooks

  2004cites this paper
• Starting highly active antiretroviral therapy: why, when and response to HAART.

  2004cites this paper
• Overview of interleukin-2 function, production and clinical applications.

  2004cites this paper
• IL-2-induced CD4+ T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation.

  2004cites this paper
• Eradication of HIV in infected patients: some potential approaches.

  2004cites this paper
• Study conduct, monitoring and data management in a trinational trial: the OPTIMA model

  2004cites this paper
• Phase I/II trial of intravenous recombinant interleukin-2 in HIV-infected children

  2003cites this paper
• Increased peripheral expansion of naive CD4+ T cells in vivo after IL-2 treatment of patients with HIV infection

  2002cites this paper
• Analysis of Virological Efficacy in Trials of Antiretroviral Regimens: Drawbacks of Not Including Viral Load Measurements after Premature Discontinuation of Therapy

  2001cites this paper
• The impact of HIV therapy on co-infection with hepatitis B and hepatitis C viruses

  2001cites this paper